Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Cancers|November 27, 2025
Patient Perception of the Relevance of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia: An International SurveyJahanzaib Khwaja, Sotirios Bristogiannis, Ibrahim Tohidi-Esfahani, et al.
Ejhaem|August 21, 2023
Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapyKatherine Rankin, Priyanka Hastak, Alexander Wong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM StudySally F Barrington, Farheen Mir, Tarec Christoffer El-Galaly, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
British Journal of Haematology|June 20, 2020
How I treat advanced Hodgkin lymphoma - a global viewPeter Hokland, Mansi Shah, Kevin David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma TrialStefano Luminari, Alexander Fossa, Judith Trotman, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Internal Medicine Journal|August 5, 2024
Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoshua W D Tobin, Greg Hapgood, Anna Johnston, et al.
Current Medical Research and Opinion|October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trialJudith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Cancers|November 27, 2025
Patient Perception of the Relevance of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia: An International SurveyJahanzaib Khwaja, Sotirios Bristogiannis, Ibrahim Tohidi-Esfahani, et al.
Ejhaem|August 21, 2023
Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapyKatherine Rankin, Priyanka Hastak, Alexander Wong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM StudySally F Barrington, Farheen Mir, Tarec Christoffer El-Galaly, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
British Journal of Haematology|June 20, 2020
How I treat advanced Hodgkin lymphoma - a global viewPeter Hokland, Mansi Shah, Kevin David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma TrialStefano Luminari, Alexander Fossa, Judith Trotman, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Internal Medicine Journal|August 5, 2024
Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoshua W D Tobin, Greg Hapgood, Anna Johnston, et al.
Current Medical Research and Opinion|October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trialJudith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Pageof 15